Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT02972840
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
- NCT02972840 ↗
- Active, not recruiting
- Acerta Pharma BV
- Focused
We haven't built an HCP commentary report on NCT02972840 (acalabrutinib in previously untreated mantle cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02972840 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Lymphoma, Mantle Cell
- Interventions
- Acalabrutinib; Bendamustine; Rituximab; Placebo
- Arms
- Acalabrutinib in combination with bendamustine and rituximab · Experimental
- Placebo in combination with bendamustine and rituximab · Placebo comparator
- Enrollment
- 635
- Primary outcomes
- Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2
- Sponsor
- Acerta Pharma BV with AstraZeneca
- Start
- Apr 5, 2017
- Primary completion
- Feb 15, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02972840 · updated Oct 8, 2026
Publications
linked from the registry- Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S, Dreyling M; ECHO investigators; ECHO Investigators. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2276-2284. doi: 10.1200/JCO-25-00690. Epub 2025 May 1. PubMed 40311141